Introduction
============

Currently, lung cancer is one of the malignant cancers in the world with the highest incidence and mortality rates ([@B1]). Therefore, the prevention of lung cancer is of utmost importance. Many studies have investigated the risk of lung cancer and tea consumption, but the conclusions were not consistent ([@B2]--[@B4]). A meta-analysis in 2009 ([@B5]) found that drinking green tea has a protective effect on lung cancer statistically, while there was no association between drinking black tea and lung cancer. Either black or green tea consumption have a protective effect on lung cancer statistically. Hence there is a controversy between the results of these two studies ([@B6]).

Smoking is a major risk factor for lung cancer ([@B7], [@B8]). In vivo animal experiments have shown that tea polyphenols can decrease the probability of tumor formation and decrease the size and peak proliferation of tumors ([@B9], [@B10]). When smoking cessation is difficult, whether tea drinking can antagonize the effects of smoking on lung cancer risk is important in the prevention of lung cancer. Intake of green tea can decrease the lung cancer risk in smoking populations ([@B11]). However, two previous systematic meta-analyses did not find that tea drinking can decrease the risk of contracting lung cancer in smoking populations.

This study collected all local and overseas published articles up till January 2017 to carry out a meta-analysis to investigate the association between tea intake in different subgroup populations and lung cancer.

Methods
=======

Tea, green tea, black tea, lung cancer, lung neoplasm, lung tumor, and lung carcinoma were used as keywords to search in the PubMed, Web of Science, the China National Knowledge Infrastructure (CNKI) and Sinomed databases. The keywords were used together or individually to search all databases from database construction until January 2017. The literature search was performed independently by two authors. All articles must fulfill the following inclusion criteria: 1) Lung cancer; 2) Case-control studies or cohort studies; 3) Exposure risk factors involves tea drinking, and study contains either OR or relative risk (RR), and its 95% CI, or these values can be computed.

Data extraction and quality assessment: The first author, publication year, study period, region, type of study, type of controls, sample size (number of cases and controls), tea drinking status, adjusted OR or RR and its 95% CI, were extracted from every article. The Newcastle-Ottawa scale (NOS) was used to evaluate the quality. Data extraction and quality assessment were also performed independently by two authors.

Statistical analysis: RevMan 5. 3 software was used for statistical analysis and the OR values and 95% CI comparing either tea drinking or highest tea intake with non-tea drinking were obtained from combining various studies. The amount of tea intake was shown by the weight of tea leaves (in grams). The intake amount in this study was readjusted and one cup of tea was defined as 2. 5 g of tea leaves ([@B2]).

The Q-test and I~2~ was used for heterogeneity testing, both P\<0. 1 and I~2~\>50% defined as the presence of heterogeneity ([@B12]). When heterogeneity presented, subgroup analysis was carried out to eliminate heterogeneity; and if heterogeneity still exists, sensitivity analysis was carried out and each study was omitted individually to see if there were studies with significant effects on heterogeneity. If heterogeneity was still presented, the random effects model was used for statistical analysis. A funnel plot was constructed to investigate publication bias ([@B13]), and an asymmetrical funnel plot shows that there is publication bias.

Results
=======

Basic information
-----------------

The initial search yielded 549 articles. Through screening of titles and abstracts, 413 articles were excluded and 60 articles were selected for data extraction after careful reading of the article. As the data from 13 articles were repeated in subsequent studies, these studies were excluded. Complete data could not be extracted from five studies and these studies were also excluded. Finally, 42 studies were included in the meta-analysis in this study ([@B3]--[@B4], [@B14]--[@B53]) ([Fig. 1](#F1){ref-type="fig"}). There were 19, 433 lung cancer patients and 718, 854 controls. 30 case-control studies, with 17 population-based case-control studies, one mortality-based case-control study and the remainder were hospital-based case-control studies. Case-control studies included 14578 lung cancer patients and 180574 controls. Twelve cohort studies included 543825 subjects, of which the outcome was 5085 with lung cancer. Two studies investigated the association between lung cancer and black and green tea consumption, 12 studies for green tea and seven for black tea. The remaining 21 studies did not specify the type of tea ([Table 1](#T1){ref-type="table"}).
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###### 

Characteristics of published studies on tea consumption and lung cancer risk

  ***Study***              ***Study period***   ***Country***   ***Study design***   ***Case-control or cohort***   ***Tea type***   ***OR (95%CI)***         ***NOS score (stars)***
  ------------------------ -------------------- --------------- -------------------- ------------------------------ ---------------- ------------------------ -------------------------
  Romain 2016([@B14])      1996--2001           Canada          PCC                  1111/1469                      Black            0\. 71\[0. 61, 0. 83\]   8
  Wu 2015([@B15])          2001--2010           China           PCC                  117/1196                       Green            0\. 87\[0. 70, 1. 07\]   7
  Wang 2015([@B16])        2012--2014           China           HCC                  88/84                          Tea              0\. 97\[0. 53, 1. 76\]   7
  Mai 2015([@B17])         1992--2011           US              Cohort               1137/94887                     Tea              0\. 83\[0. 71, 0. 96\]   8
  Katarzyna 2015([@B18])   2014                 Poland          PCC                  92/156                         Green            0\. 49\[0. 26, 0. 93\]   7
  Bao 2014([@B18])         2010--2013           China           HCC                  50/50                          Green            0\. 22\[0. 08, 0. 60\]   7
  Rup 2014([@B20])         2009--2012           India           PCC                  230/460                        Tea              0\. 95\[0. 61, 1. 49\]   7
  P. gnagna 2013([@B22])   2004--2005           Italy           Cohort               178/4158                       Tea              0\. 72\[0. 52, 0. 99\]   8
  Xu 2013([@B21])          2006--2012           China           HCC                  1225/1234                      Tea              0\. 98\[0. 84, 1. 15\]   7
  Yumie 2013([@B23])       2002--2009           China           Cohort               359/60733                      Tea              0\. 66\[0. 53, 0. 83\]   7
  Jin 2013([@B24])         2003--2010           China           PCC                  1424/4543                      Green            1\. 05\[0. 92, 1. 20\]   8
  Yumiel 2013([@B25])      2001--2011           China           Cohort               428/70839                      Tea              1\. 00\[0. 81, 1. 23\]   7
  Lin 2012([@B26])         2004--2008           China           HCC                  170/340                        Green            0\. 34\[0. 21, 0. 55\]   7
  Zhang 2012([@B27])       1997--2009           China           PCC                  900/133811                     Tea              1\. 16\[1. 01, 1. 32\]   8
  Bganesh 2011([@B28])     1997--1999           India           HCC                  408/1383                       Tea              0\. 24\[0. 11, 0. 55\]   6
  Jiang 2011([@B29])       2009--2011           China           HCC                  100/100                        Tea              0\. 92\[0. 53, 1. 61\]   7
  Lu 2009([@B30])          1992--1995           US              Cohort               201/38207                      Tea              0\. 81\[0. 61, 1. 08\]   7
  Han 2008([@B31])         2003--2008           China           HCC                  523/1924                       Green            0\. 56\[0. 44, 0. 73\]   7
  Zhang 2008([@B32])       2002--2006           China           PCC                  505/529                        Tea              1\. 16\[0. 89, 1. 53\]   8
  Wang 2008([@B24])        2006                 China           HCC                  363/363                        Tea              0\. 60\[0. 44, 0. 82\]   7
  Qli 2008([@B33])         1994--2001           Japan           cohort               302/41138                      Green            1\. 29\[0. 98, 1. 69\]   8
  Yan 2008([@B35])         1999--2004           US              PCC                  558/837                        Green&Black      0\. 52\[0. 42, 0. 66\]   7
  Tao 2007([@B36])         2002--2006           China           HCC                  47/94                          Tea              0\. 72\[0. 31, 1. 70\]   6
  Shinchi 2006([@B4])      1995--2005           Japan           Cohort               222/16247                      Green            1\. 13\[0. 82, 1. 56\]   8
  Hu 2002([@B39])          1994--1997           Canada          PCC                  161/483                        Tea              0\. 52\[0. 34, 0. 81\]   8
  Mattew 2005([@B37])      1995--1996           China           PCC                  122/121                        Green            0\. 83\[0. 44, 1. 54\]   7
  Ja 2005([@B38])          1982--1998           US              PCC                  993/986                        Black            0\. 95\[0. 79, 1. 13\]   6
  Nagano 2001([@B41])      1979--1994           Japan           Cohort               395/35930                      Green            0\. 86\[0. 66, 1. 12\]   9
  Zhong 2001([@B40])       1992--1994           China           PCC                  649/675                        Green            0\. 97\[0. 74, 1. 26\]   7
  Hivonen 2001([@B42])     1995--1998           Finland         PCC                  791/25643                      Tea              0\. 66\[0. 53, 0. 81\]   7
  Kei 2000([@B3])          1986--1997           Japan           Cohort               69/9483                        Green            1\. 01\[0. 62, 1. 63\]   6
  Ki 1997([@B45])          1992--1993           China           HCC                  105/105                        Tea              0\. 50\[0. 23, 1. 10\]   7
  Fredrik 1998([@B43])     1989--1995           Sweden          PCC                  124/235                        Black            1\. 23\[0. 78, 1. 96\]   8
  Maria 1998([@B44])       1994--1996           Uruguay         HCC                  427/428                        Black            0\. 78\[0. 60, 1. 02\]   7
  Alexandra 1996([@B46])   1986--1990           Netherlands     Cohort               764/120088                     Black            0\. 58\[0. 49, 0. 70\]   8
  Zheng 1996([@B47])       1986--1993           US              Cohort               312/35057                      Black            0\. 78\[0. 62, 0. 99\]   7
  Gosta 1996([@B48])       1989--1993           Sweden          PCC                  308/504                        Black            0\. 71\[0. 53, 0. 94\]   7
  Xu 1996([@B49])          1987--1993           China           PCC                  598/926                        Tea              0\. 84\[0. 68, 1. 03\]   9
  Ohno 1995([@B50])        1988--1991           Japan           PCC                  333/666                        Tea              0\. 57\[0. 39, 0. 83\]   9
  Tewes 1990([@B51])       1981--1983           China           PCC                  200/200                        Green&Black      0\. 98\[0. 66, 1. 45\]   6
  Mettlin 1989([@B52])     1982--1987           US              HCC                  569/569                        Tea              0\. 71\[0. 56, 0. 91\]   6
  Kinlen 1988([@B53])      1969--1986           UK              Cohort               718/12868                      Tea              1\. 67\[1. 31, 2. 13\]   7

PCC, population-based case-control study; HCC, hospital-based case-control study; US, United States; UK, United Kingdom

The quality evaluation scores of every article ranged from 6 to 9 points. Among these articles, 36 were high-quality articles (NOS 7--9) and the remaining articles were medium-quality articles (NOS 6) ([Table 1](#T1){ref-type="table"}).

Association of tea drinking and lung cancer
-------------------------------------------

When compared with non-tea drinking populations, tea drinking was found to have a protective effect against lung cancer (OR 0. 80, 95% CI: 0. 73--0. 87) ([Fig. 2](#F2){ref-type="fig"}). Statistically significant heterogeneity was observed (I~2~=80%, *P*\<0. 01) ([Fig. 3](#F3){ref-type="fig"}). Subgroup analyses were done in order to identify sources of heterogeneity. As shown in [Table 2](#T2){ref-type="table"}, the heterogeneity was not reduced by subgroup analysis of Tea types, Study design, Geographical region, Sex, Smoking status and Study period. When stratified analysis was conducted by study design. It was found to have a decreased OR in the case-control studies (OR 0. 76, 95% CI: 0. 68, 0. 85), but no statistically significant association in cohort studies (OR 0. 88, 95% CI: 0. 74, 1. 05).
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![Funnel plot of studies on tea consumption and lung cancer](IJPH-48-1566-g003){#F3}

###### 

Subgroup analyses of tea intake and lung cancer risk

  ***Study***           ***Number (n)***   ***OR (95%CI)***         ***Case-control or cohort(n)***   ***Heterogeneity test***   
  --------------------- ------------------ ------------------------ --------------------------------- -------------------------- ---------
  All studies           42                 0\. 80\[0. 73, 0. 87\]   19433/718854                      80                         \<0. 01
  2\. 5g/day            25                 0\. 79\[0. 68, 0. 91\]   10932/404166                      82                         \<0. 01
  Cohort                10                 0\. 89\[0. 71, 1. 11\]   4888/394604                       87                         \<0. 01
  CC                    15                 0\. 71\[0. 58, 0. 87\]   6044/9562                         79                         \<0. 01
  7\. 5g/day            16                 0\. 82\[0. 67, 1. 01\]   7652/277373                       86                         \<0. 01
  Cohort                6                  0\. 87\[0. 60, 1. 28\]   2470/234754                       93                         \<0. 01
  CC                    10                 0\. 91\[0. 70, 1. 18\]   4904/54490                        80                         \<0. 01
  Tea types                                                                                                                      
  Green tea             14                 0\. 75\[0. 61, 0. 92\]   5750/111640                       84                         \<0. 01
  Cohort                4                  1\. 02\[0. 81, 1. 28\]   988/101798                        51                         0\. 1
  CC                    10                 0\. 79\[0. 73, 0. 86\]   4762/9842                         86                         \<0. 01
  2\. 5g/day            9                  0\. 73\[0. 54, 0. 98\]   1959/104387                       76                         \<0. 01
  Cohort                4                  1\. 00\[0. 87, 1. 15\]   1511/103722                       49                         0\. 1
  CC                    5                  0\. 41\[0. 21, 0. 80\]   971/2589                          73                         \<0. 01
  7\. 5g/day            7                  0\. 69\[0. 48, 0. 98\]   1667/103926                       84                         \<0. 01
  Cohort                4                  0\. 86\[0. 74, 0. 98\]   988/101798                        90                         \<0. 01
  CC                    3                  0\. 61\[0. 44, 0. 85\]   679/2128                          59                         0\. 09
  Black tea             9                  0\. 80\[0. 70, 0. 91\]   4797/159909                       65                         \<0. 01
  Cohort                2                  0\. 78\[0. 72, 0. 84\]   1076/155250                       72                         0\. 05
  CC                    7                  0\. 82\[0. 76, 0. 90\]   3721/4659                         45                         0\. 09
  2\. 5g/day            7                  0\. 88\[0. 68, 1. 14\]   4039/158872                       87                         \<0. 01
  Cohort                2                  0\. 76\[0. 44, 1. 29\]   1076/155250                       90                         \<0. 01
  CC                    5                  0\. 94\[0. 72, 1. 23\]   2963/3622                         79                         \<0. 01
  7\. 5g/day            5                  0\. 75\[0. 56, 1. 02\]   2805/157168                       78                         \<0. 01
  Cohort                2                  0\. 81\[0. 49, 1. 36\]   1077/155250                       67                         0\. 08
  CC                    3                  0\. 68\[0. 40, 1. 16\]   1728/1918                         73                         0\. 02
  Tea unknown           21                 0\. 84\[0. 73, 0. 96\]   8627/316770                       78                         \<0. 01
  Cohort                4                  0\. 77\[0. 70, 0. 86\]   2056/254560                       0                          0\. 39
  CC                    17                 0\. 89\[0. 83, 0. 95\]   7526/119181                       76                         \<0. 01
  2\. 5g/day            9                  0\. 75\[0. 59, 0. 96\]   4934/140907                       84                         \<0. 01
  Cohort                4                  0\. 86\[0. 56, 1. 32\]   2824/137556                       92                         \<0. 01
  CC                    6                  0\. 67\[0. 58, 0. 78\]   2110/3351                         20                         0\. 29
  7\. 5g/day            5                  1\. 13\[0. 81, 1. 57\]   4258/27690                        83                         \<0. 01
  Cohort                1                  1\. 67\[1. 31, 2. 13\]   718/12868                         \-                         \-
  CC                    4                  1\. 01\[0. 71, 1. 43\]   2462/3411                         79                         \<0. 01
  Study design                                                                                                                   
  Cohort                12                 0\. 88\[0. 74, 1. 05\]   5085/538740                       84                         \<0. 01
  CC                    30                 0\. 76\[0. 68, 0. 85\]   14578/180574                      78                         \<0. 01
  Geographical region                                                                                                            
  Western population    15                 0\. 81\[0. 70, 0. 94\]   7325/329216                       79                         \<0. 01
  Cohort                6                  0\. 93\[0. 74, 1. 16\]   3310/299387                       83                         \<0. 01
  CC                    9                  0\. 73\[0. 61, 0. 88\]   4015/29829                        73                         \<0. 01
  Asian population      25                 0\. 80\[0. 70, 0. 92\]   10630/321441                      80                         \<0. 01
  Cohort                5                  0\. 94\[0. 91, 0. 98\]   1416/172637                       91                         \<0. 01
  CC                    20                 0\. 96\[0. 94, 0. 99\]   9214/148804                       75                         \<0. 01
  Sex                                                                                                                            
  Male                  11                 0\. 82\[0. 64, 1. 05\]   5183/240914                       90                         \<0. 01
  Cohort                4                  1\. 00\[0. 61, 1. 61\]   1980/150566                       94                         \<0. 01
  CC                    7                  0\. 73\[0. 55, 0. 98\]   3203/90348                        87                         \<0. 01
  Female                14                 0\. 80\[0. 67, 0. 95\]   4447/304808                       64                         \<0. 01
  Cohort                5                  0\. 93\[0. 82, 1. 06\]   1105/228461                       19                         0\. 29
  CC                    8                  0\. 90\[0. 82, 0. 97\]   3073/76121                        28                         0\. 21
  Smoking status                                                                                                                 
  Smoking               8                  0\. 80\[0. 63, 1. 01\]   3663/32347                        79                         \<0. 01
  Cohort                2                  0\. 67\[0. 56, 0. 81\]   969/29801                         0                          0\. 65
  CC                    5                  0\. 85\[0. 63, 1. 15\]   2694/2546                         80                         \<0. 01
  No-smoking            8                  0\. 67\[0. 51, 0. 89\]   2973/74512                        81                         \<0. 01
  Cohort                1                  0\. 66\[0. 53, 0. 83\]   359/60733                         \-                         \-
  CC                    7                  0\. 63\[0. 46, 0. 85\]   2545/3673                         77                         \<0. 01
  Study period                                                                                                                   
  Before 2000           22                 0\. 80\[0. 70, 0. 91\]   9660/326269                       77                         \<0. 01
  Cohort                7                  0\. 91\[0. 67, 1. 23\]   2761/291876                       89                         \<0. 01
  CC                    15                 0\. 76\[0. 67, 0. 85\]   6899/34393                        57                         \<0. 01
  After 2000            15                 0\. 75\[0. 64, 0. 89\]   7422/147484                       81                         \<0. 01
  Cohorts               2                  0\. 87\[0. 63, 1. 20\]   606/74997                         66                         \<0. 01
  CC                    13                 0\. 74\[0. 61, 0. 91\]   6457/11754                        83                         \<0. 01

CC, case-control study

All subgroup analysis by study design
-------------------------------------

### Type of tea

Green, black or unspecified tea were correlated with protection against lung cancer in the case-control studies. Black tea and tea unknow also showed protective effect in cohort studies ([Table 2](#T2){ref-type="table"}).

There were no statistical significances in consumption of more than one cup/day black tea and lung cancer. Increasing daily intake of green tea to 7. 5 g increased the protective effect against lung cancer both in case-control studies and Cohort studies ([Table 2](#T2){ref-type="table"}).

### Geographical region

There were obvious differences in the protective effect of tea drinking on lung cancer of Western and Asian countries in different study designs ([Table 2](#T2){ref-type="table"}).

### Gender

Both females and males, tea drinking had a protective effect against lung cancer the case-control studies ([Table 2](#T2){ref-type="table"}). But no statistically significant association was found in cohort studies.

### Study period

In both time periods of studies conducted before 2000 and after 2000, tea drinking showed a protective effect against lung cancer in the case-control studies. But no statistically significant association in cohort studies ([Table 2](#T2){ref-type="table"}).

### Smoking status

Tea consumption has a protective effect against lung cancer in non-smoking populations. When daily tea intake was greater than 2. 5 g, there was a protective effect of tea drinking on lung cancer in smoking populations ([Fig. 4](#F4){ref-type="fig"}). All studies showed heterogeneity but no publication bias (I2=63%, *P*=0. 01).

![Association of between 2. 5g/day tea consumption and risk for lung cancer on smoking status](IJPH-48-1566-g004){#F4}

Discussion
==========

This study showed that tea drinking had some protective effect against lung cancer. Increasing amounts of green tea intake showing a further decrease in lung cancer OR. Black tea also showed a protective effect of against lung cancer, but it didn't further decrease the OR of lung cancer by increasing the amount. This can be attributed to the differences in the production of the two tea ([@B49]). The main active component in green tea, EGCG was present in higher amounts in green tea than black tea. This could explain why increasing black tea consumption didn't increase its protective effect against lung cancer.

In smoking populations, when increased tea consumption to 2. 5 g/day, it showed a protective effect against lung cancer, which was consistent with previous studies ([@B9]). The preventive effect on lung cancer by tea could be due to the presence of polyphenols in tea. Evidence has shown that EGCG can prevent the formation of mutated cells and that EGCG can increase the activity of phase II enzymesin vivo animal studies ([@B54]--[@B57]). Phase II enzymes are involved in the detoxification of carcinogens that will be subsequently excreted ([@B58]). EGCG could induce apoptosis in cells that were damaged by carcinogens in cigarette smoke ([@B59]--[@B61]). However, smoking is considered as chronic exposure and long-term smoking has a much greater effect on lung cancer risk than just cumulative effects of daily smoking ([@B62]). Hence, long-term intake of high EGCG doses is required to reduce the damage caused by tobacco carcinogens. The types of tea involved in this study are complex, and there was no adjustment for amount of smoking, period of smoking, period of tea drinking, etc. Hence, It need for well-designed studies with larger sample sizes and better control of various confounding factors, and the inclusion of intervention and mechanistic studies, in order to more accurately verify the association of lung cancer and different amounts of different tea in smoking populations.

It showed heterogeneity in this study. Subgroup analysis of sex, smoking status, type of tea, intake amounts and other adjustment factors could not reduce the heterogeneity. The study by Kinlen et al. ([@B53]) is the source of heterogeneity when study type, region, sex and study period were used as subgroups. This study had a NOS score of 7, with large number of cases and low sensitivity, and removing it from inclusion did not cause any obvious differences in results. Therefore, the random effects model was used for data analysis in this study.

In addition, The combination of results of studies with different designs (case-control and cohort) lead to biased results, the subgroup analysis by study design of tea types (green tea, black tea and tea un-know), geographical region, sex, smoking status, study period and the amount of tea also have shown different. However, cohort study reveals a causal relationship, and case-control cannot, cohort studies are considered preferable to case-control studies in the hierarchy of scientific evidence, and Cohort studies results should play as the standard. Our results showed that significant association existed in case-control studies, but not in cohort studies. The results may be related to the difference of study design types and sample size. Participants in case-control studies were greatly less than participants included in cohort studies.

The results of this meta-analysis were limited by some factors. Firstly, some articles did not specify the type of tea. Secondly, the data from included studies were raw primary data and most studies were retrospective case-control studies that could have possible bias and confounding factors. Lastly, this study included a small number of countries such as China, Japan and the USA, etc., and the representation by these countries requires further verification. Despite these limitations, our study collected all studies published to date on the association of tea drinking and lung cancer for a meta-analysis, and results showed that tea drinking could have protective effect against lung cancer. Increasing the amount of green tea intake to 7. 5 g a day showed an increased protective effect of green tea against lung cancer. Regular intake of one cup of tea or more could antagonize the effects of smoking on lung cancer in smokers. However, larger sample sizes or prospective cohort studies are required for verification of these results and for further mechanistic studies.
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